Neuromed Pharmaceuticals and Merck & Co., Inc. Announce Agreement for Novel N-type Calcium Channel Compounds
Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, which is currently in Phase II development for the treatment of pain.
Under the terms of the agreement, Neuromed grants Merck an exclusive worldwide license to research, develop and commercialize NMED-160 and other compounds that selectively target the N-type calcium channel. Merck will make a $25 million initial cash payment to Neuromed. Neuromed will also receive research funding from Merck for two years as part of the collaborative research program, including the option to renew for an additional two years. Merck is responsible for all development costs and activities.
The successful development and launch of NMED-160 for an initial single indication on a worldwide basis would trigger milestone payments totaling $202 million. Milestones could increase to approximately $450 million if a further indication for NMED-160 is developed and approved and a further compound is developed and approved for two indications. Neuromed would also receive royalties on worldwide sales of NMED-160 and any additional compounds developed under this agreement. Additional milestone payments would be payable should further compounds be developed. Further financial terms were not disclosed.
Cyclenium Pharma Inc. and Fundación MEDINA (Fundación Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, the University of Granada and Merck Sharp and Dohme de España S.A., announced the signing of a drug discovery and collaboration agreement. The collaboration ... more
Moderna Therapeutics announced a license and collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). ... more
Sartorius Stedim Biotech (SSB) announced that TAP Biosystems, part of SSB Group since 2013, and Merck & Co., Inc. have won two awards at the prestigious 2014 BioProcess International (BPI) Awards. The awards recognize that the ambr250™ mini bioreactor system, developed as a result of this s ... more
Neuromed Pharmaceuticals Ltd. announced that it has licensed from ALZA Corporation the exclusive U.S. rights to develop and commercialize OROS(R) Hydromorphone, an extended release formulation of a potent opioid analgesic in Phase 3 clinical development.
Under the terms of the agreement Ne ... more
Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, ... more